Literature DB >> 12350250

Procedures for reliable estimation of viral fitness from time-series data.

Sebastian Bonhoeffer1, Andrew D Barbour, Rob J De Boer.   

Abstract

In order to develop a better understanding of the evolutionary dynamics of HIV drug resistance, it is necessary to quantify accurately the in vivo fitness costs of resistance mutations. However, the reliable estimation of such fitness costs is riddled with both theoretical and experimental difficulties. Experimental fitness assays typically suffer from the shortcoming that they are based on in vitro data. Fitness estimates based on the mathematical analysis of in vivo data, however, are often questionable because the underlying assumptions are not fulfilled. In particular, the assumption that the replication rate of the virus population is constant in time is frequently grossly violated. By extending recent work of Marée and colleagues, we present here a new approach that corrects for time-dependent viral replication in time-series data for growth competition of mutants. This approach allows a reliable estimation of the relative replicative capacity (with confidence intervals) of two competing virus variants growing within the same patient, using longitudinal data for the total plasma virus load, the relative frequency of the two variants and the death rate of infected cells. We assess the accuracy of our method using computer-generated data. An implementation of the developed method is freely accessible on the Web (http://www.eco.ethz.ch/fitness.html).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12350250      PMCID: PMC1691111          DOI: 10.1098/rspb.2002.2097

Source DB:  PubMed          Journal:  Proc Biol Sci        ISSN: 0962-8452            Impact factor:   5.349


  34 in total

1.  The frequency of resistant mutant virus before antiviral therapy.

Authors:  R M Ribeiro; S Bonhoeffer; M A Nowak
Journal:  AIDS       Date:  1998-03-26       Impact factor: 4.177

2.  Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro.

Authors:  P R Harrigan; S Bloor; B A Larder
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  Pre-existence and emergence of drug resistance in HIV-1 infection.

Authors:  S Bonhoeffer; M A Nowak
Journal:  Proc Biol Sci       Date:  1997-05-22       Impact factor: 5.349

4.  Virus dynamics and drug therapy.

Authors:  S Bonhoeffer; R M May; G M Shaw; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

5.  Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.

Authors:  P Borrow; H Lewicki; X Wei; M S Horwitz; N Peffer; H Meyers; J A Nelson; J E Gairin; B H Hahn; M B Oldstone; G M Shaw
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

6.  Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy.

Authors:  P S Eastman; J Mittler; R Kelso; C Gee; E Boyer; J Kolberg; M Urdea; J M Leonard; D W Norbeck; H Mo; M Markowitz
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

7.  Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215.

Authors:  J Goudsmit; A de Ronde; E de Rooij; R de Boer
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

8.  Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors.

Authors:  G Croteau; L Doyon; D Thibeault; G McKercher; L Pilote; D Lamarre
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

9.  Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events.

Authors:  E Yuste; S Sánchez-Palomino; C Casado; E Domingo; C López-Galíndez
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

10.  Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo.

Authors:  V Zennou; F Mammano; S Paulous; D Mathez; F Clavel
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

View more
  23 in total

1.  Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost.

Authors:  Caroline S Fernandez; Ivan Stratov; Robert De Rose; Katrina Walsh; C Jane Dale; Miranda Z Smith; Michael B Agy; Shiu-Lok Hu; Kendall Krebs; David I Watkins; David H O'connor; Miles P Davenport; Stephen J Kent
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 2.  The role of viral fitness in HIV pathogenesis.

Authors:  Jason D Barbour; Robert M Grant
Journal:  Curr HIV/AIDS Rep       Date:  2005-02       Impact factor: 5.071

3.  Differential equation modeling of HIV viral fitness experiments: model identification, model selection, and multimodel inference.

Authors:  Hongyu Miao; Carrie Dykes; Lisa M Demeter; Hulin Wu
Journal:  Biometrics       Date:  2008-05-28       Impact factor: 2.571

4.  The roles of five conserved lentiviral RNA structures in HIV-1 replication.

Authors:  Yang Liu; Jianbo Chen; Olga A Nikolaitchik; Belete A Desimmie; Steven Busan; Vinay K Pathak; Kevin M Weeks; Wei-Shau Hu
Journal:  Virology       Date:  2017-11-09       Impact factor: 3.616

5.  vFitness: a web-based computing tool for improving estimation of in vitro HIV-1 fitness experiments.

Authors:  Jingming Ma; Carrie Dykes; Tao Wu; Yangxin Huang; Lisa Demeter; Hulin Wu
Journal:  BMC Bioinformatics       Date:  2010-05-18       Impact factor: 3.169

6.  Dynamic models of immune responses: what is the ideal level of detail?

Authors:  Juilee Thakar; Mary Poss; Réka Albert; Gráinne H Long; Ranran Zhang
Journal:  Theor Biol Med Model       Date:  2010-08-20       Impact factor: 2.432

7.  CD4+ target cell availability determines the dynamics of immune escape and reversion in vivo.

Authors:  Janka Petravic; Liyen Loh; Stephen J Kent; Miles P Davenport
Journal:  J Virol       Date:  2008-02-13       Impact factor: 5.103

8.  Primary isolates of human immunodeficiency virus type 1 are usually dominated by the major variants found in blood.

Authors:  Yegor Voronin; Bhavna Chohan; Michael Emerman; Julie Overbaugh
Journal:  J Virol       Date:  2007-07-25       Impact factor: 5.103

9.  In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine.

Authors:  Roger Paredes; Manish Sagar; Vincent C Marconi; Rebecca Hoh; Jeffrey N Martin; Neil T Parkin; Christos J Petropoulos; Steven G Deeks; Daniel R Kuritzkes
Journal:  J Virol       Date:  2008-11-19       Impact factor: 5.103

10.  Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay.

Authors:  Hulin Wu; Yangxin Huang; Carrie Dykes; Dacheng Liu; Jingming Ma; Alan S Perelson; Lisa M Demeter
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.